Alchemia Limited
(ASX:ACL) has reported a net loss of $5.5 million for the first half of Fiscal 2014, up from $5.9 million for the same period last year.
A drop in total income for the period after the loss of an R&D tax incentive was highlighted by the company. Alchemia was also quick to highlight the encouraging results of ongoing clinical trials of advanced cancer drugs in the US, moving them closer to market.
